According to Reuters on the 30th (local time), the Chief Executive Officer of Monsef Slawi said that the AstraZeneca vaccine, which was approved for emergency use by the British government on the same day, is expected to be used in the United States in April if everything goes well.” said.
This is a delay of at least two months from the US government’s existing timetable, reported Politico, a political media outlet.
Earlier this month, he expected AstraZenek to apply for emergency use to the US Food and Drug Administration (FDA) as early as February next year.
The reason why the US government has delayed approval for urgent use of the AstraZeneca vaccine seems to be due to the effectiveness of the vaccine.
This vaccine, jointly developed by Oxford University and AstraZeneca, reaches 90% of the preventive effect if half of the dose is first inoculated and one additional dose is completely added a month later.
However, like other vaccines, if the entire dose was normally administered twice, the preventive effect dropped to 62%. The average prevention rate is 70.4%, which is lower than that of Pfizer-Bioentech (95%) and Modena (94.5%).
In fact, Slawy said, “It is important that one vaccine has a 95% prevention rate for Americans, and that the other vaccine is’X%’ (unknown),” he said. “A clear number is needed.”
[이상규 매경닷컴 기자 [email protected]]


[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]